Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(17)
•••
Comment by cpacon Jan 31, 2020 8:40am
175 Views
Post# 30624539

RE:RE:RE:RE:Thoughts on averaging up?

RE:RE:RE:RE:Thoughts on averaging up?I agree with woundedknee... there are benefits to both.  Your maximum % gain generally comes from buying stocks when they are totally bombed out... the trouble is, you have no idea how long you'll have to hold before getting that payoff, as long as you're diversified, no big deal.  However, in certain circumstances, especially in the biotech/small cap pharma space, it can be very lucrative to jump in (assuming you've done your dd in advance!) as a stock starts to spike price and volume... risks to the first strategy is dead money and potential value trap.  Risks to the second strategy is that market makers are moving the price up (or dowm) trolling for retail investors that jump at the sight of something shiny only to make a buck off of them and then drop the price back down...   If you invest long enough you start to see patterns.  I invested a bunch in ONC in the 80 cent range, but when I saw it start to move up, I actually should have added more...  I added to my ATE position yesterday... 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities